US Collaboration Growth Recent February 2024 collaboration with Prostatype Genomics AB to perform Prostatype testing in the US as a CLIA-accredited laboratory demonstrates US market entry readiness and cross-border capabilities. This opens sales opportunities to position ResearchDx as the go-to partner for international CDx programs requiring CLIA-backed testing, regulatory support, and end-to-end program execution—particularly for oncology and genomic diagnostics.

End-to-End Diagnostics ResearchDx offers an integrated path from assay concept through validation to regulatory approval within a CAP/CLIA lab. This end-to-end capability appeals to biopharma and diagnostic companies seeking single-provider accountability, faster timelines, and reduced risk across development, clinical research, manufacturing, and regulatory submission.

Companion Diagnostics A proven track record in companion diagnostics, including DEPArray HER2 and partnerships with Gemelli Biotech and Abreos Biosciences, underscores capability in biomarker test development and cross-ecosystem collaborations. This supports pursuing oncology, GI biomarker panels, and precision-dosing programs with mid-sized pharma and diagnostic device partners.

Lean Capacity With a lean team and mid-tier revenue, ResearchDx appears well-suited to deliver cost-efficient, scalable CDx development and laboratory services to small- to mid-sized biotech companies that need CAP/CLIA-compliant testing without engaging with larger CROs.

Regional Advantage Located in Irvine, California, ResearchDx benefits from proximity to a vibrant West Coast biotech ecosystem, enabling regional pilots, faster collaboration cycles, and targeted partnerships with local startups and academic collaborators.